The current FDA labels for Wegovy, Zepbound and Foundayo each carry a warning for acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing cases reported with GLP-1 receptor agonists. All three labels give the same instruction: if pancreatitis is suspected, discontinue the medicine and start appropriate management. The labels do not give a rate for how often it happens. Severe or worsening upper abdominal pain, especially with vomiting or fever, is a reason to seek urgent medical care rather than wait for a scheduled visit.
What the labels actually say
Pancreatitis is inflammation of the pancreas. It appears in the Warnings and Precautions section of each label, under a slightly different section number in each.
The Wegovy label (revised 06/2026, covering the injection and the tablets), section 5.2, says acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including Wegovy. It says that if pancreatitis is suspected, discontinue Wegovy and initiate appropriate management.
The Zepbound label (revised 08/2026), section 5.5, uses the same wording for Zepbound and gives the same instruction to discontinue if pancreatitis is suspected.
The Foundayo label (orforglipron tablets, revised 07/2026), section 5.2, says acute pancreatitis has been reported in patients treated with Foundayo, and that fatal and non-fatal hemorrhagic or necrotizing pancreatitis have been observed in patients treated with GLP-1 receptor agonists. It carries the same discontinuation instruction.
Two things the sections we reviewed do not do are worth noting. They do not state how often pancreatitis occurred, and they do not set out a separate rule for people who have had pancreatitis before. Neither point means the question is settled; it means the label text we reviewed leaves those decisions to you and your prescriber.
What pancreatitis feels like
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) describes acute pancreatitis pain as starting slowly or suddenly in the upper abdomen, sometimes spreading to the back, ranging from mild to severe, and possibly lasting several days. Other symptoms include nausea and vomiting, fever, a fast heartbeat, and a swollen or tender abdomen.
NIDDK advises seeking emergency care for severe or worsening abdominal pain or tenderness, particularly with vomiting, fever or chills, fast heartbeat, shortness of breath, or yellowing of the skin or eyes. It says these can signal serious infection, inflammation or blocked ducts, which can be fatal if left untreated.
Nausea, vomiting and abdominal discomfort are also common reactions to GLP-1 medicines in general, which is why the symptoms can be confusing. Our summary of side effects reported in labels and trials covers what is commonly reported. The difference to watch for is severity and persistence: pain that is intense, keeps getting worse, or goes through to the back is not the same as mild queasiness after a dose increase.
What to do if you suspect it
- Do not wait it out if the pain is severe. Seek urgent or emergency care, and tell the clinicians which GLP-1 medicine you take, the dose and when you last took it.
- Do not take another dose until you have been assessed. The labels say to discontinue if pancreatitis is suspected. Who makes that call, and how any later decision about the medicine is made, is for your treating clinicians.
- Contact your prescriber. Report the episode even if it settles, so it is part of your record.
Questions to ask your prescriber before starting
- Have I ever had pancreatitis, or do I have gallstones or a history of heavy alcohol use, which NIDDK lists among common causes?
- Which symptoms should make me stop and seek care the same day?
- Who do I call out of hours?
- If I get sustained severe abdominal pain, which medicines should I tell the emergency team about?
Gallbladder problems can look similar and are a separate label warning. See our companion article on GLP-1 medicines and gallstones. If you are scheduled for a procedure, see GLP-1 medicines before surgery or anesthesia, and for broader cautions see who should not take an oral GLP-1.
Common misunderstandings
- “Stomach pain on a GLP-1 is always a normal side effect.” Mild gastrointestinal effects are common, but severe or worsening pain needs assessment.
- “It only affects one brand.” All three labels reviewed here carry the warning.
- “The label gives a percentage.” The sections reviewed here describe observed cases but do not give a rate.
- “I can decide on my own whether to continue.” If pancreatitis is suspected, the label says to discontinue, and the follow-up decision belongs with your clinicians.
Questions people ask
Does the label say people with a history of pancreatitis cannot take these medicines?
In the Warnings and Precautions sections we reviewed, there is no separate restriction for people with a prior history. Talk to your prescriber about your history before you start.
Is the warning the same for the pill and the injection?
Wegovy’s label covers both its injection and its tablets and carries one pancreatitis warning. Foundayo, which is a tablet, carries its own equivalent warning.
Can I tell pancreatitis from ordinary nausea myself?
Not reliably. Severe, worsening or persistent upper abdominal pain, particularly with vomiting or fever, calls for medical assessment.
Sources
- U.S. FDA labeling, Wegovy prescribing information (revised 06/2026), section 5.2, checked 6 October 2026.
- U.S. FDA labeling, Zepbound prescribing information (revised 08/2026), section 5.5, checked 6 October 2026.
- U.S. FDA labeling, Foundayo prescribing information (revised 07/2026), section 5.2, checked 6 October 2026.
- National Institute of Diabetes and Digestive and Kidney Diseases, Symptoms & Causes of Pancreatitis, checked 6 October 2026.
Medical disclaimer. This article is informational and is not medical advice. If you have severe abdominal pain, seek urgent medical care. Do not start, stop or change a prescribed medicine without instructions from your prescriber.
Keep exploring our GLP-1 resources:
